<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666665</url>
  </required_header>
  <id_info>
    <org_study_id>12-142</org_study_id>
    <nct_id>NCT01666665</nct_id>
  </id_info>
  <brief_title>Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin</brief_title>
  <official_title>Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Massive pediatric burns are associated with a persistent and sustained hypermetabolic
      response characterized  by elevated levels of circulating  catecholamine's, cortisol, and
      glucagon's, which can cause extreme muscle wasting, immunodeficiency, and delay in wound
      healing.  Insulin and metformin have demonstrated anabolic activity with minimal associated
      side effects.  However, it is unknown whether the beneficial effects arise from tight
      euglycemic control or direct effect of insulin action.  We hypothesize that during acute
      hospitalization, administration of metformin at a dose titrated to maintain blood glucose
      between 80-180 mg/dl will accelerate wound healing and recovery in children with severe
      thermal injury and will have beneficial long-term effects on muscle strength, immune
      function, and wound healing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin treated patients will be compared to control patients.  Both groups will receive
      insulin therapy for blood glucose &gt;180mg/dl.  Insulin will be titrated according to hospital
      sliding scale.

      The use of insulin or metformin will benefit burned children by improving muscle protein
      build-up, speeding wound healing and reversing growth arrest, improving the immune response,
      and positively affecting long-term rehabilitation.

      The results of this study may initiate a change in standard of care as it is found that
      simply the reduction of blood glucose by metformin, improves patient outcomes as metformin
      can be administered without the added complication of hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Measure changes between admission and 2 years post burn</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein synthesis</measure>
    <time_frame>Measure changes between admission and 2 years post burn</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Measure changes between admission and 2 years post burn</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Hypermetabolism</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill up to 3 times per day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Sugar pill up to 3 times per day for 12 months</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 10-19

          -  Primary diagnosis of â‰¥ 20 TBSAB (Total Burn Surface Area Burn)

        Exclusion Criteria:

          -  Decision not to treat due to burn injury severity

          -  Known history of AIDS, ARC, HIV

          -  Pregnancy

          -  persistent lactic acidosis

          -  Previous existing renal failure, liver disease or hepatic dysfunction (Bilirubin
             &gt;3mg/dL, SGOT &gt;40u/L, GPT &gt;51u/L serum Creatinine &gt;3mg/dL after fluid resuscitation

          -  Pre-existing type 1 diabetes mellitus

          -  Allergies to Metformin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Reed, RN, BSN</last_name>
    <phone>409-770-6987</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Benjamin, RN, MSN</last_name>
    <phone>409-770-6731</phone>
    <email>dbenjami@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Reed, BSN</last_name>
      <phone>409-770-6987</phone>
      <email>ca2reed@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deb Benjamin, MSN</last_name>
      <phone>409-770-6731</phone>
      <email>dbenjami@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David N Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Suman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
